Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels - 11/02/19
, Silmara A.L. Montalvão, MSc, Rebeca B.B. Cancela, MD, Francesca A.R. Silva, MSc, Aline Urban, MSc, Stephany C. Huber, PhD, José Luiz R.C. Júnior, MSc, José Fábio S.D. Lana, MD, Joyce M. Annichinno-Bizzacchi, MD, PhDAbstract |
Background |
Promising results with platelet-rich plasma (PRP) in androgenetic alopecia that could be associated with platelet number and growth factor levels were described.
Objective |
Analyze the platelet countand growth factor levels in PRP and their correlation with hair growth parameters evaluated by using the TrichoScan (Tricholog GmbH, Freiburg, Germany).
Methods |
A total of 26 patients were randomized to receive 4 subcutaneous injections of PRP or saline. Hair growth, hair density, and percentage of anagen hairs were evaluated by using the TrichoScan method before injection, 15 days after the last injection, and again 3 months after the last injection. Growth factors (platelet-derived growth factor, epidermal growth factor, and vascular endothelial growth factor) were measured by the Luminex method (Millipore, Bedford, MA).
Results |
We demonstrated a significant increase in hair count (P = .0016), hair density (P = .012) and percentage of anagen hairs (P = .007) in the PRP group versus in the control group, without correlation with platelet counts or quantification of the growth factors in PRP.
Limitations |
Other growth factors that could be related to response to PRP were not evaluated.
Conclusion |
Our data favor the use of PRP as a therapeutic alternative in the treatment of androgenetic alopecia. The lack of association between platelet count, platelet-derived growth factor, epidermal growth factor, and vascular endothelial growth factor levels and clinical improvement suggest that other mechanisms could be involved in this response.
Le texte complet de cet article est disponible en PDF.Key words : alopecia, hair loss, platelet-rich plasma, PRP
Abbreviations used : AGA, EGF, PDGF, PRP, VEGF
Plan
| Funding sources: Supported by the National Council of Technological and Scientific Development. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
Vol 80 - N° 3
P. 694-700 - mars 2019 Retour au numéro
Article précédent
- The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study
- Kara E. Walton, Erin M. Garfield, Bin Zhang, Victor L. Quan, Katherine Shi, Lauren S. Mohan, Alexandra M. Haugh, Timothy VandenBoom, Pedram Yazdan, Maria Cristina Isales, Elnaz Panah, Pedram Gerami
- Epidemiology of nickel sensitivity: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data 1994-2014
- Erin M. Warshaw, Amy J. Zhang, Joel G. DeKoven, Howard I. Maibach, Donald V. Belsito, Denis Sasseville, Joseph F. Fowler, Anthony F. Fransway, Toby Mathias, Melanie D. Pratt, James G. Marks, Kathryn A. Zug, Matthew J. Zirwas, James S. Taylor, Vincent A. DeLeo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?